Catalyst Funds Management Pty LTD Aldeyra Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 600 shares of ALDX stock, worth $2,646. This represents 0.0% of its overall portfolio holdings.
Number of Shares
600Holding current value
$2,646% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
116Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$40.9 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$24.1 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$16.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$16 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$8.3 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $257M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...